PHARMACOSMOS A/S: Financial statements 2022
CVR: 15517085
Source: annual report 2022, Danish Business Authority
01/05/2021 – 30/04/2022
PHARMACOSMOS A/S (CVR 15517085) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 876,811,000 and a net result of DKK 170,038,000 compared with DKK -136,005,000 the year before. That is an increase of 12.1% compared with the year before. The profit margin was 19.4%. Equity in the 2022 report amounted to DKK 807,467,000. The solvency ratio was 50.8%. The company had 468 employees in the financial year.
- Revenue
- DKK 876,811,000
- Gross Profit
- DKK 545,455,000
- Profit/Loss
- DKK 170,038,000
- Equity
- DKK 807,467,000
- Total Assets
- DKK 1,590,166,000
- Employees
- 468
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 876.8M | 545.5M | 170M | 807.5M | 468 |
| 2021 | 782.2M | 464.9M | -136M | 642.8M | 352 |
| 2020 | 609.1M | 328.9M | 56.5M | 884M | 258 |
| 2019 | 573.1M | 318M | 102.1M | 827M | 236 |
| 2018 | 542.2M | 314.5M | 69.1M | 720.8M | 208 |
Official annual report
Keep an eye on PHARMACOSMOS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of June 28, 2022, Tobias Sidelmann Christensen is registered as adm. dir. of PHARMACOSMOS A/S.
As of June 28, 2022, Lars Christensen has stepped down as adm. dir. of PHARMACOSMOS A/S.
About PHARMACOSMOS A/S
PHARMACOSMOS A/S is a Danish company of the type Aktieselskab based in Holbæk, founded in 1991. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named PHARMACOSMOS PHARMACEUTICALS A/S and SOLOCHEM A/S. The management consists of Tobias Sidelmann Christensen, Claes Christian Strøm and Henrik Parker. The board consists of Jacob Tolstrup (chair), Lars Christensen, Lars Green and Martin Holst Lange. The company is owned by PHARMACOSMOS HOLDING A/S. The company has 327 employees (2026). In 2026, the company reported revenue of DKK 2,176,000,000 and a net result of DKK 714,000,000 compared with DKK 1,622,000,000 the year before. Equity in the 2026 report amounted to DKK 2,775,000,000.